Eli Lilly Just Got a Bundle of Good News: Time to Buy?

Mitrade
coverImg
Source: DepositPhotos

The magic isn't over for Eli Lilly (NYSE: LLY). Though the pharmaceutical giant isn't performing as well in the second half of the year as it did in the first, it still has plenty of fuel for growth. In fact, the drugmaker recently received some welcome news that jolted its stock price.


The bears might point out that Eli Lilly's shares still look too expensive: The company's trailing price-to-earnings (P/E) ratio tops 86 -- the average for the healthcare industry is less than a quarter of that at 18.


Do recent developments make Eli Lilly's shares worth investing in despite its expensive valuation?


LLY Chart

LLY data by YCharts


Eli Lilly's potential competitor comes up short


Eli Lilly is a leader in the weight loss sector thanks to tirzepatide, which it markets as Zepbound. The drugmaker's only noteworthy competitor is Novo Nordisk, the maker of Wegovy. These two are old foes: They have been battling for supremacy in the diabetes market for decades. However, considering Wegovy's and Zepbound's success, many other companies are looking to challenge Eli Lilly and Novo Nordisk.


One of them is Amgen, whose leading candidate, MariTide, recently reported positive phase 2 clinical test data. The market was not impressed with MariTide's performance, though. The medicine led to an average weight loss of up to 20% in 52 weeks in the study involving overweight or obese patients, with no weight loss plateau observed.


Amgen did not indicate whether this was a placebo-adjusted result. In a phase 3 study, Zepbound was associated with an average weight loss of up to 22.5% in patients after 72 weeks, compared to 4.3% for those taking a placebo. MariTide still has a long way to go, but considering many analysts saw it as one of the most promising challengers to the Eli Lilly and Wegovy duopoly, the fact that it did not quite meet expectations is good news for the current leaders.


A boost on the regulatory front


There is more good news for Eli Lilly as far as its weight loss programs are concerned. President Joe Biden recently announced a proposal whereby this class of medicines would be covered under Medicare and Medicaid. That would make them accessible to millions of additional patients and, potentially, help their sales soar even more. Eli Lilly would be one of the beneficiaries if this measure passes. There is no guarantee that it will happen, but the market is optimistic about this development. Eli Lilly's shares jumped meaningfully on the news.


Plenty of reasons to buy


Eli Lilly's shares recently dropped after its third-quarter results did not meet expectations. The company's revenue increased by 20% year over year to $11.4 billion, while its adjusted earnings per share of $1.18 was much higher than the $0.10 reported in the year-ago period. Companies with high P/E ratios are held to higher standards -- these results would be excellent for almost any peer pharmaceutical company. Still, the recent news that helped jolt its stock price highlights two crucial points.


First, it will be difficult for anyone other than Novo Nordisk to challenge Eli Lilly in the weight loss market. The company has been developing breakthrough medicines in adjacent areas for a long time and was first to market in this field. Don't underestimate the experience that comes with past successes and failures. Eli Lilly still has plenty of weight loss candidates in the pipeline, including one it is calling Triple G since it mimics the action of three different hormones: GLP-1, GIP, and glucagon.


Zepbound mimics the action of the first two, and it's clear how effective it is. Eli Lilly's next-gen weight loss therapy could be even more so. Second, there is a significant and probably unmet demand for these medicines. Some people simply can't afford them, so the prospect of the government helping foot the bill is appealing and could be another tailwind for Eli Lilly. Beyond the weight loss market, Eli Lilly has plenty of drugs that generate solid sales and plenty of attractive pipeline candidates.


They include Kisunla, a recently approved Alzheimer's disease therapy; and muvalaplin, an investigational phase 2 medicine that just posted positive results in lowering lipoprotein (a), or LP(a), levels in adults at high risk of cardiovascular events. LP(a), a type of fat, can cause cardiovascular problems in high levels. No medicine is currently approved in the U.S. to lower LP(a), so there is an unmet need here.


Eli Lilly will earn plenty of approvals and label expansions in the next five years. The company's revenue and earnings should continue growing rapidly, especially as newer products like Kisunla start contributing. So, despite its high P/E, the drugmaker can deliver excellent returns. Investors should still strongly consider purchasing shares of Eli Lilly.

Read more

  • Gold Price Forecast: Gold Tumbles Below $3,900 as Trump Says No Need for Iran Deal; Can October PPI Spur a Rebound?
  • * The content presented above, whether from a third party or not, is considered as general advice only.  This article should not be construed as containing investment advice, investment recommendations, an offer of or solicitation for any transactions in financial instruments.

    goTop
    quote
    Related Articles
    placeholder
    Weekly Report: The index rose 2.5% while Nvidia fell 12.7% — two equity divergences, one should closeThe S&P 500 rose 2.51% to 7,561.67 and the QQQ rose 3.63% to 679.89 last week, while Nvidia fell 12.75% to 162.85 — a sixth straight weekly loss and 32% below its October record. In the same five sessions, energy equities rose 5.42% while WTI fell 2.52%. Both pairs normally move together (60-day correlations of +0.64 and +0.58). This report ranks which divergence closes first, with the trigger for each.
    Author  Irene Q.
    13 hours ago
    The S&P 500 rose 2.51% to 7,561.67 and the QQQ rose 3.63% to 679.89 last week, while Nvidia fell 12.75% to 162.85 — a sixth straight weekly loss and 32% below its October record. In the same five sessions, energy equities rose 5.42% while WTI fell 2.52%. Both pairs normally move together (60-day correlations of +0.64 and +0.58). This report ranks which divergence closes first, with the trigger for each.
    placeholder
    Anthropic is six times oversubscribed at $1.4 trillion while Nvidia is down 32% — the AI trade has two pricesAnthropic lists on Nasdaq as ANT on Thursday at $70 ~ $78 a share, raising up to $64.4 billion at a target valuation near $1.4 trillion, and the book is reportedly six times covered. In the same six weeks, Nvidia has fallen 32% and the QQQ is 10.9% below its October peak. Private capital and public markets are marking the same AI complex at two very different prices. This piece separates the two books: what the S-1 shows, who is anchoring the $26 billion private placement, and what Thursday's debut would have to do to change the public tape.
    Author  Irene Q.
    13 hours ago
    Anthropic lists on Nasdaq as ANT on Thursday at $70 ~ $78 a share, raising up to $64.4 billion at a target valuation near $1.4 trillion, and the book is reportedly six times covered. In the same six weeks, Nvidia has fallen 32% and the QQQ is 10.9% below its October peak. Private capital and public markets are marking the same AI complex at two very different prices. This piece separates the two books: what the S-1 shows, who is anchoring the $26 billion private placement, and what Thursday's debut would have to do to change the public tape.
    placeholder
    Nvidia reports tomorrow with an interim CEO — $108 billion is the easy numberNvidia closed at 162.85 on Friday, down 12.75% on the week and 32% below its 6 October record, with market value down to $3.92 trillion. The Q3 bar is $108 billion ±2%, and consensus already sits at $108.7 ~ 108.8 billion, so the revenue line is not where the surprise lives. The number that decides the reaction is the 71 ~ 72% Q4 gross-margin trough, followed by a Q4 guide against a $124.9 billion consensus. This piece prices the print, marks the 158.39 line and lays out the three scenarios in a table.
    Author  Irene Q.
    13 hours ago
    Nvidia closed at 162.85 on Friday, down 12.75% on the week and 32% below its 6 October record, with market value down to $3.92 trillion. The Q3 bar is $108 billion ±2%, and consensus already sits at $108.7 ~ 108.8 billion, so the revenue line is not where the surprise lives. The number that decides the reaction is the 71 ~ 72% Q4 gross-margin trough, followed by a Q4 guide against a $124.9 billion consensus. This piece prices the print, marks the 158.39 line and lays out the three scenarios in a table.
    placeholder
    Today’s Market Recap: Nvidia Drops Over 4% After Jensen Huang Resigns, AMD and Broadcom Both Rise Over 5% On November 12, the three major U.S. stock indices closed slightly lower. Nvidia announced that Jensen Huang had stepped down immediately as CEO and director, draggi
    Author  TradingKey
    Nov 13, Fri
    On November 12, the three major U.S. stock indices closed slightly lower. Nvidia announced that Jensen Huang had stepped down immediately as CEO and director, draggi
    placeholder
    US October PPI Preview: Fed Rate Hike Expectations Rise, PPI May Be Key Variable; How Will US Stocks, Dollar, and Gold Move?On Friday (Nov. 13) Eastern Time, the U.S. will release the October Producer Price Index (PPI). Following the October CPI once again exceeding expectations, the market will look to the PP
    Author  TradingKey
    Nov 12, Thu
    On Friday (Nov. 13) Eastern Time, the U.S. will release the October Producer Price Index (PPI). Following the October CPI once again exceeding expectations, the market will look to the PP
    Live Quotes
    Name / SymbolChart% Change / Price
    LLY
    LLY
    0.00%0.00

    US Stocks Related Articles

    • 10 Best Day Trading Platforms for Beginners and Active Traders in 2026: A Practical Guide
    • How To Invest in SpaceX Stock in 2026? Everything Investors Need to Know
    • Practice Trading Us Stocks? These Are 10 Best Stock Trading Demo Apps For Beginners
    • ​5 Best Paper Trading Platforms for 2026 (Free Demo Accounts for Beginners & Traders)
    • Wall Street’s Top 10 US Stocks for 2026 vs What Reddit Is Actually Buying
    • Is Mitrade Right for You? A Complete Guide on How to Start Trading CFDs in 5 Steps

    Click to view more